| Nira Pollock, MD | |
|
Beth Israel Deaconess Medical Center, 110 Francis St. Lowry Bldg Suite Gb, Boston, MA 02215 | |
| (617) 632-0760 | |
| Not Available |
| Full Name | Nira Pollock |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine - Infectious Disease |
| Location | Beth Israel Deaconess Medical Center, Boston, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881713030 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 220226 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Nira Pollock, MD Beth Israel Med Ctr, 110 Francis St. Lowry Bldg., Ste Gb, Boston, MA 02215 Ph: (617) 632-0760 | Nira Pollock, MD Beth Israel Deaconess Medical Center, 110 Francis St. Lowry Bldg Suite Gb, Boston, MA 02215 Ph: (617) 632-0760 |
News Archive
About 40 percent of the global population is at risk for contracting dengue - the most important mosquito-borne viral infection and a close "cousin" of the Zika virus - and yet, no effective treatment or safe licensed vaccine exists.
Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.
Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today announced that on August 11, 2011 it filed a 510(k) application with the Food and Drug Administration (FDA) for clearance of its hemodiafiltration system.
A team of scientists, led by researchers at the University of California, San Diego School of Medicine and Zacharon Pharmaceuticals, have developed a simple, reliable test for identifying biomarkers for mucopolysaccharidoses (MPS), a group of inherited metabolic disorders that are currently diagnosed in patients only after symptoms have become serious and the damage possibly irreversible.
› Verified 7 days ago
Kaitlyn My-tu Lam, MBBS Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-724-7738 | |
Kui Toh Gerard Leong, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 55 Fruit Street, Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-8862 | |
Ruma Rajbhandari, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-525-6841 | |
Alaka Ray, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2066 | |
Meghan E Sise, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114 Phone: 617-726-2862 | |
Aaron Dickstein, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Box 233, Boston, MA 02111 Phone: 617-636-5883 Fax: 617-636-9292 | |
Dr. Felicia Elizabeth Patch, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 801 Massachusetts Ave, Crosstown 2, Boston, MA 02118 Phone: 617-414-4376 Fax: 617-414-4676 |